share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K:外國發行人報告
SEC announcement ·  04/09 16:05
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale...Show More
Clearmind Medicine Inc., a clinical-stage biotech company, has issued a letter to shareholders on April 9, 2024, outlining significant progress in its research and development efforts, particularly with its flagship compound CMND-100. The CEO, Dr. Adi Zuloff-Shani, highlighted the company's advancements in treating alcohol use disorder (AUD) and other mental health conditions. Clearmind has received approval from the Israeli Ministry of Health for a Phase I/IIa clinical trial for CMND-100, which has shown promising results in pre-clinical studies without inducing hallucinations. The company has completed a Type A meeting with the FDA, formed a Data and Safety Monitoring Board, secured IRB Approval in Israel, and announced U.S. clinical trial sites at Johns Hopkins University and Yale School of Medicine. Clearmind also reported progress in obesity and metabolic disorders research, a collaboration with CTS Ltd., and the expansion of its patent portfolio. Looking forward, Clearmind anticipates initiating the Phase I/IIa trial for AUD, expanding strategic alliances, advancing obesity research, and progressing its MEAI-based alcohol substitute for the consumer market. The company's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0' respectively.
處於臨床階段的生物技術公司Clearmind Medicine Inc. 已於2024年4月9日致股東的一封信,概述了其研發工作的重大進展,特別是其旗艦化合物 CMND-100 的研發進展。首席執行官阿迪·祖洛夫-沙尼博士重點介紹了該公司在治療酒精使用障礙(AUD)和其他心理健康狀況方面取得的進展。Clearmind 已獲得以色列衛生部的批准,可進行 CMND-100 的 I/IIa 期臨床試驗,該試驗在臨床前研究中顯示出令人鼓舞的結果,不會誘發幻覺。該公司已經完成了與美國食品藥品管理局的A型會議,成立了數據和安全監測委員會,獲得了以色列IRB的批准,並宣佈在約翰·霍普金斯大學和耶魯醫學院設立...展開全部
處於臨床階段的生物技術公司Clearmind Medicine Inc. 已於2024年4月9日致股東的一封信,概述了其研發工作的重大進展,特別是其旗艦化合物 CMND-100 的研發進展。首席執行官阿迪·祖洛夫-沙尼博士重點介紹了該公司在治療酒精使用障礙(AUD)和其他心理健康狀況方面取得的進展。Clearmind 已獲得以色列衛生部的批准,可進行 CMND-100 的 I/IIa 期臨床試驗,該試驗在臨床前研究中顯示出令人鼓舞的結果,不會誘發幻覺。該公司已經完成了與美國食品藥品管理局的A型會議,成立了數據和安全監測委員會,獲得了以色列IRB的批准,並宣佈在約翰·霍普金斯大學和耶魯醫學院設立美國臨床試驗基地。Clearmind還報告了肥胖和代謝障礙研究的進展、與CTS有限公司的合作以及其專利組合的擴大。展望未來,Clearmind預計將啓動澳元的I/IIa期試驗,擴大戰略聯盟,推進肥胖研究,並推進其基於MEAI的酒精替代品在消費市場上取得進展。該公司的股票在納斯達克和法蘭克福證券交易所上市,股票代碼分別爲 “CMND” 和 “CWY0”。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息